Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Weekly Digest – 04 July to 10 July

Approval  ·  Weekly Digest - 08 August to 14 August 2026
Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer

Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer Hengrui Pharma’s HER2-targeted ADC Aiweida has been approved in China for the treatment of adults with HER2-positive colorectal […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 08 August to 14 August 2026
AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer

Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer AbbVie’s ELAHERE has been approved in Russia for the treatment of epithelial ovarian, […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 01 August to 07 August 2026
Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy

Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in the EU as […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 01 August to 07 August 2026
FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease

Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease Novartis announced that the U.S. FDA has approved Pluvicto in combination with […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 25 July to 31 July 2026
AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer AstraZeneca Pharma India announced that the Central […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 25 July to 31 July 2026
ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and mNSCLC

Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and mNSCLC ImmunityBio announced that the United Arab Emirates has granted marketing authorization […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 18 July to 24 July 2026
Biokin Pharma announces approval of Iza-bren in China for the treatment of recurrent/metastatic ESCC

Weekly Digest – July 2026 Weekly Digest – July 2026 17 July 2026: Biokin Pharma announces approval of Iza-bren in China for the treatment of recurrent/metastatic ESCC Biokin Pharma announced that China’s NMPA has approved Iza-bren for the treatment of […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 11 July to 17 July 2026
U.S. FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility

Weekly Digest – July 2026 Weekly Digest – July 2026 10 July 2026: U.S. FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility The U.S. FDA has approved PADCEV plus KEYTRUDA as neoadjuvant […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 04 July to 10 July
China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 7 July 2026: China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer Astellas have announced that China’s National Medical Products Administration has accepted the […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 04 July to 10 July
Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority review

Weekly Digest – July 2026 Weekly Digest – July 2026 8 July 2026: Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority review Hengrui Pharma’s HER2-targeted antibody-drug conjugate Trastuzumab rezetecan has had its new […]

by Sandhya Ramalingam

Continue Reading
123
Page 2 of 3


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id